CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern

CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 
4:15 p.m. Eastern 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/14/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company working to
save lives through blood purification, today announced that
management will host a shareholder update conference call on
Wednesday, August 21st at 4:15 p.m. Eastern. Management kindly asks
all interested participants to submit their questions to Alliance
Advisors at  
Conference Call Details:
 Date: Wednesday, August 21, 2013 
4:15 p.m. Eastern
 Participant Dial-In: (480) 629-9712
 Live Webcast:
 Submit Questions to: 
It is recommended that participants dial in approximately 10 minutes
prior to the start of the 4:15 p.m. Eastern call. There will also be
a simultaneous live webcast of the conference call which can be
accessed through the following audio feed link and archived recording
of the conference call available under the Investor Relations section
of the company website at  
About CytoSorbents Corporation 
 CytoSorbents is a critical care
focused therapeutic device company specializing in blood
purification. CytoSorb(R), the Company's flagship product, is
approved in the European Union as a safe and effective extracorporeal
cytokine filter, designed to reduce the "cytokine storm" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury, and pancreatitis. These are conditions where the mortality is
extremely high, yet no effective treatments exist. The goal of
CytoSorb(R) is to prevent or treat multiple organ failure, the cause
of nearly half of all deaths in the intensive care unit, with little
available to improve clinical outcome. CytoSorbents' purification
technologies are based on biocompatible, highly porous polymer beads
that can actively remove toxic substances from blood and other bodily
fluids by pore capture and surface adsorption. CytoSorbents has
numerous products under development based upon this unique blood
purification technology, protected by 32 issued US patents and
multiple applications pending, including HemoDefend(TM),
ContrastSorb, DrugSorb, and others. Additional information is
available for download on the Company's website: 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222 
Valter Pinto
(914) 669-0222 x201 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378 
Press spacebar to pause and continue. Press esc to stop.